Flavamed contains ambroxol, a metabolite of bromhexine. Flavamed is approved for mucolytic treatment of cough in patients with acute or chronic respiratory disorders. There are for the time being no data that suggests any advantages in using Flavamed rather than other expectorants as i.e. acetylcysteine, neither in acute nor chronic cough. No significant controlled trials on the effect of Flavamed on acute cough exist. As for COPD (Chronic Obstructive Pulmonary Disease), one double-blinded, placebo-controlled randomized trial has been conducted. The trial proceeded for one year, and no clinically relevant effect on the number of exacerbations was found.
Flavamed is marketed as an effervescent (soluble) tablet of 60 mg and cough syrup of 6 mg/mL. The recommended dosage for adults and children over 12 years of age is 30 mg 3 times a day for 2-3 days, and subsequently 30 mg twice daily. The dosage can be increased to 60 mg twice daily. Flavamed is sold over the counter in pharmacies and is not subject to reimbursement.